Business Combination - Additional Information (Detail)			8 Months Ended	12 Months Ended
	Sep. 13, 2018	May 04, 2017 USD ($) shares	Dec. 31, 2017 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Business Acquisition [Line Items]
Reverse stock split of common stock	0.03
Share exchange ratio		1-for-1 basis
Debt converted in to equity		10,558
Conversion of stock | shares		229,450
Transaction costs			$ 2,183,671		$ 2,183,671
Change in tax rate				21.00%	34.00%
Increase in goodwill from recorded adjustments				$ 490,676	$ 15,573,822
Discount rate		23.00%
Goodwill impairment loss				490,676	35,919,695
Goodwill				0		$ 18,758,421
Revenue				10,331,168	10,738,322
Net loss				(39,171,152)	(46,425,390)
Change in fair value of derivatives					90,191
Interest expense				297,090	162,139
Acquisition-related Costs [Member]
Business Acquisition [Line Items]
Nonrecurring pro forma adjustments					1,512,423
Common Stock Warrants [Member]
Business Acquisition [Line Items]
Conversion of stock | shares		22,024
Restricted Stock Units (RSUs) [Member]
Business Acquisition [Line Items]
Conversion of stock | shares		1,325
Series B Preferred Stock [Member]
Business Acquisition [Line Items]
Conversion of preferred stock		$ 19,976
Common Stock Class A [Member]
Business Acquisition [Line Items]
Common stock issued | shares		229,450
PharmAthene [Member]
Business Acquisition [Line Items]
Reverse stock split of common stock		0.02497
Equity interests acquired		58.20%
Total fair value of consideration		$ 44,742,737
Outstanding unvested options | shares		252
Stock options estimated fair value		$ 15,173
Operating loss carryforwards				$ 965,583
Operating loss carryforwards, expiration date				Jan. 01, 2023
Increase tax refund receivable due to adjustments to the allocation of the purchase consideration					44,700
Reduce deferred tax liability due to adjustments to the allocation of the purchase consideration					4,535
Increase in goodwill due to adjustments to the allocation of the purchase consideration					$ 49,235
Change in tax rate				35.00%	34.00%
Goodwill		$ 16,064,498
Revenue			1,765,212
Net loss			36,003
Nonrecurring pro forma adjustments					$ (52,315,978)
Interest expense					148,521
Dividends accrued but not yet paid			$ 163,068		163,068
PharmAthene [Member] | Stock Compensation Expense [Member]
Business Acquisition [Line Items]
Nonrecurring pro forma adjustments					$ 66,180